In today’s ACT Brief, we examine how ZIP code shapes trial availability and enrollment, why smaller biotechs hold outdated views of APAC sites, and how FDA approved Pimjetmi for symptomatic tenosynovial giant cell tumor.
Commentary|Podcasts|August 22, 2023
Where Digital Health Technology Intersects with Pharma
Author(s)Lisa Henderson, Andy Studna, Senior Editor
Innovative pharma companies are stepping up to integrate digital health technology to advance pharmaceutical drug and medical device development, in both the healthcare and research worlds, to achieve better measurements and outcomes.
Chris Economos, Vice President and Head of Life Sciences at Eko, discusses his career journey from pharma to digital health technology, where he recognized the power of AI and digital health to improve clinical care and research. He discusses the current ability of AI in the future use of digital measurements and biomarkers to improve clinical trials, as well as outcomes.
About the speaker
Chris Economos, as Vice President and Head of Life Sciences for Eko, cultivates strategic and commercial relationships with medical technology and pharmaceutical companies. Economos was previously SVP of Corporate Development for physIQ Inc, as well as roles with Healthy Interactions, Abbvie, ZymoGenetics, and Deloitte. He holds a Bachelor of Science degree from Vanderbilt University and an MBA from the Indiana University Kelley School of Business.
About the ACT Podcast
The editors of Applied Clinical Trials bring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.
Related to this article
In today’s ACT Brief, we examine three priorities for first-time APAC sponsors, how continuous glucose monitoring should be used in diabetes trials, and why FDA is requiring a new eye-related warning across GLP-1 medications.
In today’s ACT Brief, we examine why APAC is attractive for global Phase III programs, how clinical research professionals can turn a failed pivotal trial into a redesigned success, and how FDA approved Sunharbo to reduce recurrent stroke risk.
In today’s ACT Brief, we examine how China’s trial startup timelines compare with those in the US and Europe, whether AI-drafted clinical study reports speed drug development, and how Bimzelx compared with Skyrizi in psoriatic arthritis.
In today’s ACT Brief, we examine why APAC inspection findings mirror those in the US and Europe, how key risk indicators should be read together, and how FDA granted accelerated approval to a subcutaneous antibody therapy for recurrent head and neck cancer.
In today’s ACT Brief, we examine why outdated views of Asia Pacific trial sites persist, how community access gaps reflect both patient costs and site infrastructure, and how VeonGen has aligned with the FDA on a pivotal gene therapy trial design.
In today’s ACT Brief, we examine how capturing friction in real time can reveal site burden, how OpenAI and Mistral compare on clinical trial matching, and how Boehringer Ingelheim is licensing early-stage oncology programs from SBP Group.
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.
Trending on Applied Clinical Trials Online
1
Why So Many Patients From Underrepresented Groups Are Never Asked to Join a Trial
2
Continuous Glucose Monitoring in Diabetes Clinical Trials: Endpoints, Regulatory Guidance, and Operational Best Practices
3
Why APAC Clinical Trial Sites Deserve a Second Look: Q&A with James Cheong, Precision for Medicine
4
FDA Reportedly Pauses Commissioner’s National Priority Voucher Pilot as Existing Reviews Continue
5